Loading your page…
Marketing-authorisation holder
4 medicines in 2 countries, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
4 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Lacosamide Adroiq | Lacosamide | EU (EMA) | Authorised | 2023 |
| LACOSAMIDE ADROIQSoluzione per infusione | Lacosamide | Italy | Authorised | |
| Sugammadex Adroiq | Sugammadex | EU (EMA) | Authorised | 2023 |
| SUGAMMADEX ADROIQSoluzione iniettabile | Sugammadex | Italy | Authorised |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| European Union (EMA) | 2 | 2 | 0 | CompaniesAll medicines |
| Italy | 2 | 2 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Report an error or request removalCorrections from the company itself are welcome.
